Sonus meets with FDA on EchoGen

Article

It could be as long as 10 months before Sonus Pharmaceuticals gets its EchoGen ultrasound contrast agent on the market, as it moves to comply with the Food and Drug Administration’s concerns about the agent’s new drug application (NDA). Sonus

It could be as long as 10 months before Sonus Pharmaceuticals gets its EchoGen ultrasound contrast agent on the market, as it moves to comply with the Food and Drug Administration’s concerns about the agent’s new drug application (NDA). Sonus of Bothell, WA, met with the FDA on April 27 to discuss the NDA after receiving a not-approvable letter for EchoGen in February (SCAN 3/18/98).

Sonus reported that it plans to submit an amendment to EchoGen’s NDA in the next two to four months to respond to the FDA’s concerns regarding the manufacturing processes for EchoGen, including chemistry and analytical methods validation, as well as the company’s analysis of animal and clinical data in the application. Once Sonus submits the amendment, the FDA could take up to six months to review it before rendering a decision.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.